It's Here, It's There, There's Fungi Everywhere: A Case Series Utilizing Rezafungin for Invasive Candidiasis.

IF 4.7 3区医学 Q1 INFECTIOUS DISEASES

Infectious Diseases and Therapy Pub Date : 2025-03-11 DOI:10.1007/s40121-025-01120-7

Jacob M Keck, Ryan K Dare, Mitchell B Jenkins, Juan C Rico, Luke Grisham, Jennifer McDonald, Alina Viteri, Robert W Bradsher

引用次数: 0

Abstract

Rezafungin is a long-acting echinocandin with broad coverage against Candida. Rezafungin has primarily been indicated for candidemia, with limited literature available on its use for infections outside of the bloodstream. Herein, three patient cases are presented from an academic medical center. Infectious processes presented include drug-resistant mucosal candidiasis, prosthetic joint infection, and candidemia involving Candida auris. In all three cases, patients received rezafungin. Clinical response was demonstrated in all patients as was tolerability of rezafungin. Together these cases provide further evidence for the use of rezafungin, including its use for treatment of invasive infections other than candidemia.

查看原文本刊更多论文

它在这里，它在那里，到处都是真菌：使用Rezafungin治疗侵袭性念珠菌病的病例系列。

Rezafungin是一种长效针叶菌素，具有广泛的抗念珠菌作用。Rezafungin主要用于念珠菌病，关于其用于血流外感染的文献有限。在此，三个病人的情况下，提出了从一个学术医疗中心。感染过程包括耐药粘膜念珠菌病、假体关节感染和念珠菌感染。在所有三个病例中，患者都接受了rezafungin。所有患者均表现出临床反应和rezafungin的耐受性。这些病例共同为使用rezafungin提供了进一步的证据，包括将其用于治疗除念珠菌外的侵袭性感染。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infectious Diseases and Therapy Medicine-Microbiology (medical)

CiteScore

8.60

自引率

1.90%

发文量

136

审稿时长

6 weeks

期刊介绍： Infectious Diseases and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of infectious disease therapies and interventions, including vaccines and devices. Studies relating to diagnostic products and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to, bacterial and fungal infections, viral infections (including HIV/AIDS and hepatitis), parasitological diseases, tuberculosis and other mycobacterial diseases, vaccinations and other interventions, and drug-resistance, chronic infections, epidemiology and tropical, emergent, pediatric, dermal and sexually-transmitted diseases.